Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Health-Related Values Discussions with Patients Undergoing Allogeneic and Autologous Stem Cell Transplant: Feasibility and Acceptability of an Early Primary Palliative Care Intervention.
Cohen AG, Cho C, Patterson E, Magaldi J, Doga T, Naputo K, Alvarez K, Giles E, Yang G, Hoque A, Kramer D, Devlin S, Nemirovsky D, Rosa WE, Goldberg JI, Perales MA, Epstein AS, Nelson JE, Landau H. Cohen AG, et al. Among authors: devlin s. Transplant Cell Ther. 2024 Dec 17:S2666-6367(24)00810-8. doi: 10.1016/j.jtct.2024.12.009. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39701287
A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantation.
Fein JA, McAuliffe A, Fischer K, Brady O, Devlin SM, Willumsen S, Ozcan G, Montanaro P, Pristyazhnyuk Y, DiGiuseppe J, Lahoud OB, Perales MA, Pfister DG, Giralt S, Dailey M, Yu PP, Sauter CS. Fein JA, et al. Among authors: devlin sm. Leuk Lymphoma. 2024 Dec 6:1-8. doi: 10.1080/10428194.2024.2434171. Online ahead of print. Leuk Lymphoma. 2024. PMID: 39641218
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis.
Jurgens EM, Firestone RS, Chaudhari J, Hosszu K, Devlin SM, Shah UA, Landa J, McAvoy DP, Lesokhin AM, Korde N, Hassoun H, Tan CR, Hultcrantz M, Shah GL, Landau HJ, Chung DJ, Scordo M, Eren OC, Dogan A, Giralt SA, Park JH, Rivière I, Brentjens RJ, Smith EL, Wang X, Usmani SZ, Mailankody S. Jurgens EM, et al. Among authors: devlin sm. J Clin Oncol. 2024 Dec 4:JCO2401785. doi: 10.1200/JCO-24-01785. Online ahead of print. J Clin Oncol. 2024. PMID: 39631041
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy.
Boardman AP, Gutgarts V, Flynn J, Devlin SM, Goldman A, Tomas AA, Fein JA, Slingerland JB, Parascondola A, Lin RJ, Scordo M, Dahi PB, Giralt S, Palomba ML, Salles G, Nath K, Walji M, Corona M, Park JH, Shah GL, Perales MA, Jaffer-Sathick I, Shouval R. Boardman AP, et al. Among authors: devlin sm. Haematologica. 2024 Nov 21. doi: 10.3324/haematol.2024.286021. Online ahead of print. Haematologica. 2024. PMID: 39568416 Free article.
Mapping Implementation Strategies to Address Barriers to Pre-Exposure Prophylaxis Use Among Women Through POWER Up (Pre-Exposure Prophylaxis Optimization Among Women to Enhance Retention and Uptake): Content Analysis.
Johnson AK, Devlin SA, Pyra M, Etshokin E, Ducheny K, Friedman EE, Hirschhorn LR, Haider S, Ridgway JP. Johnson AK, et al. Among authors: devlin sa. JMIR Form Res. 2024 Nov 15;8:e59800. doi: 10.2196/59800. JMIR Form Res. 2024. PMID: 39546769 Free PMC article.
Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes.
Valtis YK, Devlin S, Shouval R, Rejeski K, Corona M, Luna De Abia A, Rivas-Delgado A, Luttwak E, Cassanello G, Landego I, Schöder H, Bedmutha A, Boardman A, Shah GL, Scordo M, Perales MA, Salles G, Palomba ML, Shah UA, Park JH. Valtis YK, et al. Among authors: devlin s. Blood Adv. 2025 Jan 14;9(1):151-161. doi: 10.1182/bloodadvances.2024014555. Blood Adv. 2025. PMID: 39471490
398 results